Prevention of dengue vaccines in the pipeline  by Rey, L.C.
16th ICID Abstracts / International Journal of Infectious Diseases 21S (2014) 1–460 29
Type: Invited Presentation
Final Abstract Number: 11.004
Session: Surveillance of Zoonotic Diseases
Date: Thursday, April 3, 2014
Time: 15:45-17:45
Room: Room 1.60
Update on viral hemorrhagic fevers
R. Swanepoel
University of Pretoria, Pretoria, South Africa
Viral hemorrhagic fevers (VHF) are characterized by a propen-
sity for human-to-human spread and high death rates; properties
which render them liable to control by the state and necessitate
the use of high security laboratories for handling the etiological
agents. However, not all strains of the viruses concerned cause
hemorrhagic signs or highly lethal disease, while a variety of other
pathogens pose equally hazardous health problems. Hence, for
regulatory purposes it has been found more logical to classify
high consequence pathogens according to deﬁned biorisk groups.
Among the familiar VHFs of Africa, Marburg and Ebola ﬁloviruses
have been less active recently than 5-10 years ago, but there have
been advances in understanding the ecology and pathogenesis of
these viruses, and in developing candidate vaccines and therapeu-
tics. Meantime, the emergence of new pathogens has continued
apace, including a new arenavirus and a rhabdovirus causing hem-
orrhagic fever in Africa, and a phlebovirus in China.
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Etioepidemiology of dengue in Latin America
B. Zambrano
Sanoﬁ Pasteur, Montivideo, Uruguay
Dengue is a mosquito-borne viral disease. It is estimated that
50-100 million people are infected and a half a million cases due
to DHF/DSS and ≈25,000 deaths occur annually worldwide. The
region of the Americas have experienced a dramatic increase in
the number of reported cases over the last thirty years, evolv-
ing from a low to a high endemicity situation, with indigenous
transmission in almost all countries. The 4 dengue serotypes are
circulating in the region, sometimes with a hyperendemic pattern
(co-circulation of 2 or more serotypes) in countries like Venezuela
and Colombia. Epidemic patterns of 3-5 years have been observed,
with an increasing number of reported cases in the last 5 years.
Caseshavebeen reportedwith a seasonality pattern related to rainy
season in most of countries. There is a trend of severe cases in
younger ages in the last 10 years in Latin America, compared to
what had been observed previously. To 15 Nov 2013, record ﬁg-
ures of more than 2 million of dengue cases had been reported to
PAHO (Pan American Health Organization), 32,270 of them con-
sidered as severe, the incidence rate was of 404.35 per 100,000
population, 1,175 deaths and case fatality rate of 0.05 Somemacro-
determinant factorsmay contribute to the increasing dengue cases,
like: Unprecedented population growth, unplanned and uncon-
trolled urbanization, increasing poverty, population movement
(migration, tourism), climatic change. Countries continue with the
efforts for the disease control through speciﬁc actions against
Aedes mosquitoes and PAHO’s Integrated Management Strategy
for dengue prevention and control, however additional measures
should be implemented like the development of effective dengue
vaccines to reinforce the current strategies
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The spread of dengue into Africa
A.A. Sall
Institut Pasteur de Dakar, Dakar, Senegal
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Prevention of dengue vaccines in the pipeline
L.C. Rey
Federal University of Ceara, Fortaleza CE, Brazil
Dengue burden is an important issue in Africa, Asia and the
Americas, with nearly 2 billion people exposed. Vector control is so
far the onlymeasure availableworldwide to stop the growingnum-
ber of cases. But control measures are not effective, since trends of
erratic urbanization and its consequences like water supply and
storage, and waste disposal, largely favors the mosquito spread-
ing. Vaccination is the most promising preventive intervention
and deserves heavy efforts. Denguevirus is a member of Flavivirus
Genus, andmanyof its componentshavebeen successfully targeted
for vaccine development, such as West Nile fever (veterinary),
Japanese encephalitis, tick-borne encephalitis andyellow fever, but
none of these viruses has four serotypes as denguevirus. Single
serotype (monovalent) dengue vaccines has been pursued since
the 1950s in Asia, when viral attenuation was obtained in sev-
eral mouse brain tissue passages, but a tetravalent vaccine was
never come to trial. Latter in the 1980s, natural attenuation process
in cell culture (PDK cells) gave rise to new live vaccines, through
the cooperation of Mahidol University in Thailand and the Walter
Reed Institute ofUSA.Monovalent PDK cell vaccineswere immuno-
genic, but when all four serotypes were put together interference
among serotypes appeared; two of these vaccines have been aban-
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doned in the last decade. However a new generation of vaccines
wasborn,usingbiomolecular techniques. Called “chimerivax” tech-
nique, it uses the yellow fever (YF) 17D vaccine where the original
genes of proteins prM and E where replaced by genes coding the
proteins prM and E of each denguevirus, creating four YF virions
expressing DEN 1,2,3,4 antigens (in phase III clinical trials). Other
similar attempts have produced DEN/DEN chimeric virions, where
an attenuated serotype, is the frame of a 4-component dengue
vaccine (in phase I/II clinical trials). These vaccines show good per-
spectives of safety and immunogenicity against dengue disease.
Finally, at least two inactivated vaccines (prM and E proteins of
four serotypes) are being developed at phase I clinical trials. In
conclusion, several dengue vaccines are in the pipeline, with good
perspectives for dengue prevention.
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Mediators of vascular leak in dengue
G.N. Malavige
University of Sri Jayawardenapura, Nugegoda, Sri
Lanka
Increased vascular permeability leading to plasma leakage is
the hall mark of dengue haemorrhagic fever (DHF). The media-
tors that cause vascular leak in currently not know. As platelet
activating factor (PAF) and other lipid mediators such as sphin-
gosine 1 phosphate (S1P) are associated with increase in vascular
permeability in many disease conditions, we set out to investigate
the role of these mediators in acute dengue infection. Serum PAF,
PAF receptor, PAF-AH and SIP levels were done 45 patients with
conﬁrmed acute dengue infection and 12 healthy dengue seropos-
itive individuals. Serum PAF levels, IL-10, dengue NS1 antigen and
dengue IgG antibody levels were done in 15 patients in daily blood
samples collected throughout the course of their hospital stay. Dis-
ease severity was classiﬁed based on the WHO 2011 guidelines
for diagnosis and management of dengue infection. The effect of
PAF, PAF antagonists and serum of dengue serum on human umbil-
ical vein endothelial cell lines (HUVEC) were evaluated by confocal
microscopy. PAF levels were signiﬁcantly higher in patients with
acute dengue infection (p=0.001) when compared to healthy indi-
viduals. Although not signiﬁcant the PAF levels were higher in
those with DHF (mean 343.2, SD±437.7 ng/ml) when compared
to those with DF (mean204.7, SD±484.4 ng/ml). PAF-AH levels
were also signiﬁcantly higher in those with DHF. The PAF and IL-
10 levels were highest just before the onset of the critical phase,
which is associated with plasma leakage. In PAF levels in patients
with uncomplicated DF remained below 100ng/ml throughout
the course of the illness. The S1P levels were signiﬁcantly lower
(p =0.005) in those with DHF (mean 5.76, SD±3.1mol/l) when
compared to thosewithDF (mean11.34; SD6.1mol/l) andhealthy
individuals. Imaging studies using HUVEC cell lines showed that
ZO-1 protein was disrupted at higher concentration of PAF which
was blocked by use of a PAF antagonist. PAF levels appear to be
signiﬁcantly high in patients with acute dengue infection and SIP
signiﬁcantly lower suggesting that the delicate balance between
these mediators might have a role in the pathogenesis of vascular
leak in acute dengue.
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WHO ART guidelines and beyond: Should CD4
count be a barrier to ART initiation
F. Venter
Wits Reproductive Health and HIV Institute,
Johannesburg, South Africa
WHO 2013 guidelines suggest that the CD4 threshold for
antiretroviral initiation be elevated from 350 to 500 cells/ul, in
patients with HIV. This follows many (but not all) developed coun-
try guidelines, which have elevated the threshold or done away
with it altogether, based on data suggesting clinical beneﬁt, as well
as modelling studies showing signiﬁcant public health beneﬁt in
arresting new transmission. However, there has been criticism of
the new recommendation on many fronts, ranging from question-
ing of the absolute clinical beneﬁt to the individual starting early,
the extent of the HIV prevention beneﬁts of earlier initiation, to
concerns regarding the cost and operational feasibility of expand-
ing analreadyambitiousprogrammebeyondcurrentCD4strata.On
the other side, a signiﬁcant number of clinicians and public health
advocates have called for WHO to remove the CD4 threshold alto-
gether, to simplifyprogrammes, aswell asmaximise theprevention
power of antiretrovirals. This presentation will explore both sides
of the recommendation.
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Monitoring antiretroviral therapy in
resource-limited settings
K. Ruxrungtham
HIV Netherlands Australia Thailand Research
Collaboration, The Thai Red Cross AIDS Research
Center and Chulalongkorn University, Bangkok,
Thailand
The recent WHO 2013 consolidated ART guidelines have rec-
ommended to initiated ART earlier in asymptomatic HIV-infected
individuals when CD4 count <500 cells/mm3. Several resource-
limited countries are thus implementing earlier ART. Ideally, in
settings where primary HIV resistance transmission is low and
patients are very well adhere to the treatment regimen; most
patients will have a long-term virological control regardless of VL
